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Sir,
With great interest, we have studied the work by Smith et al
(2008) that describes presence of CD133 receptors on gastro-
intestinal cancer cells and states that an antibody-drug conjugate
against this receptor led to delayed growth response in gastric
cancer cell lines as well as in mice. The work supports the
hypothesis that CD133þ cells act as tumorigenic cancer cells.
In reaction to the published work, we have investigated that
quantitative CD133 expression in patients with different stages of
gastric cancer compared with normal mucosa or chronically
inflamed tissue. Interestingly, this expression was reduced in
cancer patients and was significantly decreased in patients with
more advanced stages of cancer (see Figure 1). These results
question the role of CD133 as a marker for tumorigenic gastric
cancer cells or question the hypothesis of the potential of such
stem cells.
In contrast to the work by Smith et al (2008) we determined
mRNA levels by RT–PCR, as we were not able to establish a
specific antibody binding. This may be because of the scarcity of
such tumorigenic cancer cells. In colon cancer, only 2.5% of all
cancer cells were found to express CD133 receptors (Ricci-Vitiani
et al, 2007). If CD133þ cancer cells act as tumorigenic cells
although being able to divide, our data question the function of
such cells as they were actually reduced in patients with more
advanced stages and distant metastasis; in our study, the greatest
CD133 expression was found in mucosal stages that are known to
have lymph node metastasis only in very rare cases (Gotoda et al,
2000).
Alternatively, CD133 receptors may be expressed on other cells
than tumour cells. Our data point towards a potential role of
CD133 in angiogenesis as VEGF-R2 receptors were closely related
to CD133 expression in our collective (correlation coefficient:
0.306; P¼0.008). Endothelial progenitor cells (EPCs), a subgroup
of bone marrow-derived stem cells, were shown to express CD133
receptors together with VEGFR-2, CD34 and VE-cadherin (Peichev
et al, 2000). Here, CD133 expression was reduced in advanced
stages of cancer, paralleling VEGF-R2 expression and microvessel
density. Thus, it seems to be that the decrease of CD133 mRNA in
advanced stages of gastric cancer reflects reduced angiogenesis and
simultaneously reduced presence of endothelial precursor cells.
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Figure 1 (A) CD133 mRNA expression in human gastric tissue samples
from 92 patients. mRNA copy numbers were normalised to 10
6 GAPDH
copies. The histological presentations are normal stomach without H. pylori
infection or inflammation (n¼20), H. pylori infection without severe
alterations (n¼20) and gastric cancer tissue (n¼52). (B) CD133 mRNA
expression in human gastric cancer tissue samples from 52 patients.
Samples were grouped into carcinomas limited to the mucosa (pT1m)
(n¼16) and carcinomas exceeding the mucosa (pT1sm, pT2, pT3)
(n¼36).
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www.bjcancer.comOverall, the earlier observation of a functional importance of
CD133 may be related to the inhibition of angiogenesis and vessel
formation, but not directly to a functional role of these receptors in
cell proliferation of malignant tumour cells.
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